by Solural Pharma | Jun 30, 2017 | News
Ascelia Pharma AB acquires Oncoral Pharma ApS and its novel tablet based proprietary formulation of the chemotherapeutic agent, irinotecan, which today is only available as an intravenous infusion product. Solural Pharma will continue to support Ascelia Pharma with...
by Solural Pharma | Jun 20, 2017 | News
The United States Patent and Trademark office has issued the Solural patent “Solid Oral Dosage Form of Testosterone Derivative”.
by Solural Pharma | Jun 1, 2017 | News
Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral Irinotecan tablet product developed by Solural Pharma in combination therapy with oral capicitabine tablet in adult patients with solid tumors.
by Solural Pharma | Jun 29, 2016 | News
Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting...
by Solural Pharma | Jul 16, 2015 | News
Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral irinotecan product developed by Solural Pharma
by Solural Pharma | Apr 22, 2015 | News
Solural Pharma ApS receives Certificate of GMP Compliance of a Manufacturer issued by the Danish Health and Medicines Authority
by Solural Pharma | Feb 17, 2015 | News
The Danish Innovation Fund has granted Solural Pharma 1.5 mio DKK for together with Contera Pharma ApS (part of Bukwang Pharmaceuticals Co Ltd) , Dr. Sandra Klein, the University of Greifswald and Erweka Gmbh, to develop a new innovative product for the treatment of...
by Solural Pharma | Dec 2, 2014 | News
Solural Pharma initiates first human dosing on the SOL-924 new product formulation developed by Solural Pharma ApS. The project is being developed in partnership with an undisclosed major US partner.
by Solural Pharma | Oct 7, 2014 | News
Herlev Hospital has received a grant from the Danish Cancer Society of 1 mio DKK to support human testing of the Oncoral Pharma oral irinotecan product
by Solural Pharma | Jul 17, 2014 | News
Solural Pharma ApS enters into an exclusive licensing agreement with an undisclosed US partner on the development of a new proprietary product developed by Solural Pharma.
